In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
Denosumab-adet (Degevma) is FDA-approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and hypercalcemia of malignancy.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
Advertisement
Advertisement
Trending on OncLive
1
OncLive Weekly News Quiz (10/9/2026): Did You Miss Crucial Colon Cancer, Myeloma, Breast Cancer, and Lung Cancer Updates?
2
FDA Grants Fast Track Designation to PSV359 for Advanced FAP-Positive Solitary Fibrous Tumors
3
Nonrelapse Mortality, Safety, and Long-Term Trajectory After GVHD Control
4
Belumosudil and the Evolving Role of Ibrutinib in Chronic GVHD
5